Clinical trial · no report yet · Phase 3
NCT03233711
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
- NCT03233711 ↗
- Active not recruiting
- National Cancer Institute (NCI)
- 12 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 6 | |
| YouTube | 4 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Anal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Anal Margin Squamous Cell Carcinoma; Stage IIB Anal Cancer AJCC v8; Stage III Anal Cancer AJCC v8
- Interventions
- Biopsy Procedure; Biospecimen Collection; Colonoscopy; Computed Tomography; Digital Rectal Examination; High Resolution Anoscopy; Magnetic Resonance Imaging; Nivolumab; Patient Observation; Proctoscopy; Sigmoidoscopy; X-Ray Imaging
- Arms
- Arm A (nivolumab) · Experimental
- Arm B (clinical observation) · Other
- Enrollment
- 344 (estimated)
- Primary outcomes
- Disease free survival
- Sponsor
- National Cancer Institute (NCI) with Canadian Cancer Trials Group
- Start
- Jul 5, 2018
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03233711 · updated Oct 1, 2026